The Spanish Bioindustry Association (AseBio), where Laminar Pharma is a member, has published its latest annual report on the state of the biotech sector in Spain, with updated data from 2020. ...
Meliterapia, la revolución de los lípidos con sello valenciano Read the article | Download ...
Pablo Escribá: "En Alicante ultimaremos nuestro tratamiento de tumores antes de salir al mercado" ...
Laminar Pharma has signed an agreement to sponsor the charity Sonrisa Médica, whose mission is to make hospital stays bearable for children, through laughter and magic....
“If someone has done it before, I can do it too – if no one has done it, I can be the first”: for 30 years, this compass has guided the prolific scientific career of Dr. Pablo Escribá, founder and CEO of Laminar Pharma....
Alicante Science Park Foundation (PCA) and Laminar Pharmaceuticals have signed today the contract by which the biotechnology company is linked to the PCA....
Alicante Science Park Foundation (PCA) and Laminar Pharmaceuticals have signed today the contract by which the biotechnology company is linked to the PCA....
In 2020, biologist Gema Malet Engra joined our company after a successful 15-year career in fundamental and applied research in Oncology at several international research centers. ...
Laminar Pharma, la biotecnológica española valorada en 70 millones de euros a punto de dar el salto a bolsa, quiere ser "un punto de inflexión en la terapia del cáncer" ...
Women’s contributions to science and technology have always been lower than men’s due to the social and sexual separation in these jobs. ...